Today: 14 April 2026
Subscribe
Browse Category

NASDAQ:RGLS 27 June 2025

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • Goldman Sachs Cuts India Nifty Year-End Target by 14% as $100 Oil Pressures Earnings
    April 14, 2026, 4:32 AM EDT. Goldman Sachs has slashed its 2026 earnings growth forecast for India to 8% from 16%, triggering a 14% cut in the Nifty year-end target. The surge in crude oil prices above $100 per barrel, driven by tensions in the Strait of Hormuz, has exacerbated pressures on India's market. Sachin Jasuja of Centricity WealthTech said the earnings story was already weakening before oil spiked, emphasizing that elevated energy costs are squeezing margins across sectors, from factories to agriculture. Rising inflation, expected at 4.6%, may prompt the Reserve Bank of India to hike rates further, hurting interest-sensitive sectors. Structural changes from the new Income Tax Act 2025 add to headwinds. With foreign investment at a 15-year low, market stability hinges increasingly on domestic retail investors.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.04.2026

14 April 2026
LIVEMarkets rolling coverageStarted: April 14, 2026, 12:00 AM EDTUpdated: April 14, 2026, 4:42 AM EDT Goldman Sachs Cuts India Nifty Year-End Target by 14% as $100 Oil Pressures Earnings April 14, 2026, 4:32 AM EDT. Goldman Sachs has slashed its 2026 earnings growth forecast for India to 8% from 16%, triggering a 14% cut in the Nifty year-end target. The surge in crude oil prices above $100 per barrel, driven by tensions in the Strait of Hormuz, has exacerbated pressures on India's market. Sachin Jasuja of Centricity WealthTech said the earnings story was already weakening before oil spiked, emphasizing that
Marvell Stock Hits Record High After Nvidia’s $2 Billion Move and Amazon AI Chip Push

Marvell Stock Hits Record High After Nvidia’s $2 Billion Move and Amazon AI Chip Push

13 April 2026
Marvell Technology shares rose 2.1% to $131.22 Monday, hitting a record after Nvidia’s $2 billion investment and renewed optimism over Amazon’s AI chip business. The stock earlier touched $135.18. Barclays upgraded Marvell and raised its price target to $150, citing surging demand for optical products in AI data centers. Nvidia and Marvell plan to link custom chips for Nvidia’s NVLink Fusion platform.
Intel Stock Rally Extends as $100 Billion April Run Draws Fresh Wall Street Bets

Intel Stock Rally Extends as $100 Billion April Run Draws Fresh Wall Street Bets

13 April 2026
Intel shares climbed $2.09 to $64.47 by late morning Monday, extending a rally that has added over $100 billion in value across eight sessions. The surge follows a raised price target, new deals with Google and Elon Musk’s Terafab, and Intel’s $14.2 billion buyback of Apollo’s Fab 34 stake. The stock is up 69% in 2026 after an 84% gain last year. Intel reports first-quarter results April 23.
Nebius Stock (NBIS) Jumps as BofA Backs AI Trade, but Downgrade Flags Valuation Risk

Nebius Stock (NBIS) Jumps as BofA Backs AI Trade, but Downgrade Flags Valuation Risk

13 April 2026
Nebius Group shares climbed 7.4% to $155.74 by midday Monday after Bank of America raised its price target to $175, despite Freedom Capital Markets downgrading the stock to Hold. The Amsterdam-based AI infrastructure firm recently secured a five-year deal with Meta worth up to $27 billion and holds over $40 billion in supply contracts with Microsoft and Meta. Nebius also closed $4.34 billion in convertible debt and sold $2 billion in warrants to Nvidia.
Go toTop